About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, July 21st, 2017

The QualityStocks
Daily Stock List


RealBiz Media Group, Inc. (RBIZ)

Stock Commander, Juicy Penny Stocks, Wallstreet Profiler, DSR News, Trading Wall St, SmallCapVoice, TopPennyStockMovers, Ascending Stocks, Fortune Penny Stocks, HotStockProfits, PennyDoctor, Pumps and Dumps, Value Penny Stocks, Beacon Equity Research, InvestorSoup, Penny Stock Craze, Penny Stocks Finder, Stock Preacher, Stock Roach, StockHideout, and SuperStockTips, 007 Stock Chat, and PennyStockSpy reported earlier on RealBiz Media Group, Inc. (RBIZ), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

RealBiz Media Group, Inc. operates two business segments. One is a global food subsidiary (Verus Foods) that sells products to customers around the world. The other is a real estate digital media and technology company. In 2014, RealBiz Media acquired ReachFactor, Inc. ReachFactor is a social media marketing platform. RealBiz Media Group’s shares trade on the OTC Markets Group’s OTCQB.

ReachFactor helps real estate agents and brokerages build their online visibility, connect with customer prospects, and turn those prospects into new customers. RealBiz has in place exclusive agreements with key players such as Century21 and ERA systems. The RealBiz video platform is constructed on 20 patents and developed totally in-house over 10 years. It is the premier video technology platform for high speed, high quality video production.

RealBiz Media’s Verus Foods sells products to customers internationally. Verus markets under its own brand primarily to supermarkets, hotels, and other members of the wholesale trade. This year, Verus plans to pursue a three-pronged development program through the addition of cold-storage facilities, product line expansion, and new vertical farm-to-market operations.

Verus Foods’ initial emphasis is on frozen foods, specifically meat, poultry, seafood, vegetables, and French fries. Verus has a major regional presence in the Middle East and North Africa (MENA) and sub-Saharan Africa (excluding Office of Foreign Assets Control (OFAC)-restricted nations). Verus has deep roots in the Gulf Cooperation Council (GCC) nations.

Regarding RealBiz’s proprietary video processing technology, it makes it one of the leaders in providing home video tours to the real estate industry. The Company’s customer base includes greater than 350,000 real estate agents and brokers. RealBiz has access to the nation’s largest real estate companies with many approved vendors and national contracts. Its strength is focused on its proprietary video production and distribution technology.

RealBiz provides a series of products. This includes a consumer website (www.nestbuilder.com), an agent-only platform called Nestbuilder Agent 2.0, an agent social media and marketing solution called the aforementioned ReachFactor, a growing microvideo app (MVA) network, virtual tours, and mobile apps. The Company’s proprietary technology allows the automated conversion of data, including text and pictures of home listings, into video with voice and music. Upon creation, the videos can automatically be distributed to manifold media platforms for consumer viewing.

RealBiz Media Group, Inc. (RBIZ), closed Friday's trading session at $0.018, even for the day, on 394,063 volume with 7 trades. The average volume for the last 60 days is 265,717 and the stock's 52-week low/high is $0.0151/$28.00.

Relmada Therapeutics, Inc. (RLMD)

The Observer, PCG Advisory, Streetwise Reports, SmallCap Network, Penny Stock Bets, StreetAuthority Financial, Dividend Opportunities, Investors Alley, Trade of the Week, Wallstreetbuzz, Investopedia, ProfitableTrading, and WallstreetsHotteststocks reported on Relmada Therapeutics, Inc. (RLMD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Relmada Therapeutics, Inc. is a clinical-stage, specialty pharmaceutical company. It concentrates on developing novel versions of proven drug products in combination with new chemical entities, which potentially address areas of high unmet medical need in the treatment of pain. Relmada Therapeutics has a diverse portfolio of lead products at different stages of development. The Company is headquartered in New York, New York.

Relmada Therapeutics is developing novel therapies for the treatment of central nervous system (CNS) diseases. Its lead products are d-Methadone (REL-1017), its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine - MepiGel (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine - BuTab (REL-1028), the Company’s oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), the Company’s abuse resistant, sustained release dosage form of the opioid analgesic levorphanol.

Relmada Therapeutics’ BuTab (REL-1028) is its investigational, oral formulation of buprenorphine, an opioid that is broadly used to treat addiction and chronic pain. The design of BuTab is to be delivered orally and reach safe and effective blood levels of buprenorphine by way of the gastrointestinal route of administration because of its modified release profile.

Relmada Therapeutics received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in June of 2016 for the management of postherpetic neuralgia. In July of 2016, the Company announced it was granted a patent from the European Patent Office (EPO) for compositions and methods of use for its extended release oral levorphanol (3-hydroxy-N-methylmorphinan).

The Patent (EP 2 448 406 B1), titled "Extended Release Oral Pharmaceutical Compositions of 3-hydroxy-N-methylmorphinan" extensively covers its SECUREL™ technology platform and LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules). The patent is not scheduled to expire until 2030. Furthermore, Relmada Therapeutics subsequently announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 9,468,611 for "d-Methadone for the Treatment of Psychiatric Symptoms."

In April of this year, Relmada Therapeutics announced that the FDA granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), Relmada’s novel N-methyl-D-aspartate (NMDA) receptor antagonist in development for the adjunctive treatment of major depressive disorder. The Company is planning to advance the development program for REL-1017 to a Phase 2a randomized, double-blind, placebo-controlled study in patients with major depressive disorder. The study will evaluate changes in depressive symptoms and the safety, tolerability, and pharmacokinetics of two dose levels of REL-1017 as rapid acting adjunctive treatment in patients during a seven-day dosing period and 14-day observation period.

Last month, Relmada Therapeutics announced that Dr. Maurizio Fava was named Chair of the newly formed Dextromethadone Scientific Advisory Board of Relmada.  In this role, Dr. Fava will be a key advisor for the development program for dextromethadone (REL 1017), including preclinical and clinical research, and regulatory strategies, in coordination with the Company’s established team of advisors and key opinion leaders.

Relmada Therapeutics, Inc. (RLMD), closed Friday's trading session at $0.75, even for the day, on 11,823 volume with 21 trades. The average volume for the last 60 days is 6,077 and the stock's 52-week low/high is $0.61/$2.15.

Pharma-Bio Serv, Inc. (PBSV)

Zacks reported earlier on Pharma-Bio Serv, Inc. (PBSV), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. Its main business is Food and Drug Administration (FDA) and other global regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico.

Pharma-Bio Serv is headquartered in Dorado, Puerto Rico. In addition, the Company has operations in the United States, Ireland, and Spain. The Company lists on the OTCQB.

Pharma-Bio Serv’s global team includes leading engineering and life science professionals, quality assurance managers, and directors. Furthermore, the Company’s services include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts.

Pharma-Bio Serv supports its clients via the product lifecycle. This includes research and development (R&D) Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. Moreover, this includes Quality Systems; Technology Transfer; Validation, and Manufacturing Controls & Process Support.

Pharma-Bio Serv’s divisions include Scienza Labs, the aforementioned PharmaServ Academy, and Metrologix. Scienza Labs provides microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, as well as instrument rental.

Last month, Pharma-Bio Serv announced that Net Revenues for the three and six months ended April 30, 2017 were $3.9 and $8.0 million, respectively. This represents a decrease of roughly $1.2 and $2.1 million, or 23.6 percent and 20.6 percent, respectively, versus the same periods in 2016. The decrease for the three months ended April 30, 2017, versus the same period in 2016, is primarily attributable to a decline in projects in the Puerto Rico, United States, and Brazil consulting markets of $1.1, $0.1 and $0.1 million, respectively, partially counterbalanced by a gain in the Calibrations operation of roughly $0.1 million.

The decline for the six months ended April 30, 2017, versus the same period in 2016 is primarily attributable to a decrease in projects in the Puerto Rico, United States, and Brazil consulting markets for $1.9, $0.1 and $0.1 million, respectively, in addition to a decrease in the Puerto Rico Lab operation of $0.1 million, partially counterbalanced by a gain in Calibrations operation of roughly $0.2 million.

Pharma-Bio Serv, Inc. (PBSV), closed Friday's trading session at $0.65, even for the day. The average volume for the last 60 days is 1,328 and the stock's 52-week low/high is $0.55/$1.00.

Graphite One Resources, Inc. (GPHOF)

Investing News, OTC Markets, and MarketWatch reported on Graphite One Resources, Inc. (GPHOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Graphite One Resources, Inc. engages in the acquisition, exploration, and evaluation of graphitic mineral properties in the United States. Graphite is a vital material for electric vehicle batteries and energy storage systems. The United States is currently 100 percent import-dependent for its graphite supply. The Company continues to develop its Graphite One Project, where it could potentially become an American producer of high grade Coated Spherical Graphite (CSG), which is integrated with a domestic graphite resource. Graphite One Resources is headquartered in Vancouver, British Columbia.

The Graphite One Project is proposed as a vertically integrated enterprise to mine, process, and manufacture high grade CSG chiefly for the lithium-ion (Li-ion) electric vehicle battery market. As stated in the Company's Preliminary Economic Assessment (PEA), potential graphite mineralization mined from its Graphite Creek Property is expected to be processed into concentrate at a graphite processing plant.

The proposed processing plant would be situated on the Graphite Creek Property located on the Seward Peninsula, approximately 60 kilometers north of Nome, Alaska. CSG and other value-added graphite products would likely be manufactured from the concentrate at Graphite One’s proposed graphite product manufacturing facility, the location of which is the subject of additional study and analysis. The Company’s intention is to make a production decision on the Graphite One Project upon the completion of a feasibility study.

This past February, Graphite One Resources announced that it entered into a Memorandum of Understanding (MOU) with the Alaska Industrial Development and Export Authority (AIDEA) to explore opportunities to collaborate on the development of the Graphite One Project.

MOU highlights include the exploration of opportunities to maximize job creation and economic development by way of the Graphite One Project; and facilitation of project permitting and development of a structure for community and stakeholder dialogue. Highlights of this MOU also include options and opportunities for AIDEA to participate in infrastructure financing of project facilities related to the Graphite One Project.

Recently, Graphite One Resources announced that it received a site assessment report for its advanced-materials graphite refinery facility prepared by AIDEA (the AIDEA Report) with cooperation from the Alaska Department of Commerce, Community and Economic Development and the Department of Natural Resources.

The AIDEA Report is the first product of the MOU entered into by AIDEA and Graphite One announced on February 16, 2017. The four potential locations identified in the AIDEA Report are Homer, Kenai, Port Mackenzie, and Seward. Graphite One has notified AIDEA of its interest in coordinating in-depth site assessments with the communities identified in the AIDEA Report.

Last week, Graphite One Resources announced that it filed on SEDAR an amended PEA report on its Graphite One Project after being chosen by the British Columbia Securities Commission for a technical disclosure review. Unchanged are the recommendations and conclusions described in the original report dated February 2, 2017, and as summarized in Graphite One Resources’ press release of January 30, 2017. The amendments made are all non-substantive in kind.

Graphite One Resources, Inc. (GPHOF), closed Friday's trading session at $0.046, up 2.22%, on 2,350 volume with 1 trade. The average volume for the last 60 days is 100,167 and the stock's 52-week low/high is $0.0406/$0.09.

Capstone Companies, Inc. (CAPC)

Marketbeat, AllPennyStocks, and PennyStocks Forever reported earlier on Capstone Companies, Inc. (CAPC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Capstone Companies, Inc. is a public holding company headquartered in Deerfield Beach, Florida. The Company is a designer of innovative LED lighting solutions, including power failure lighting. It is also an innovator of other specialty consumer products that are distributed around the world, in countries including Australia, Iceland, Japan, Korea, Mexico, North America, South America, Spain, Taiwan and the United Kingdom.

By way of its wholly-owned subsidiaries, Capstone Industries, Inc., Capstone Lighting Technologies, LLC, and Capstone International HK, Ltd., the Company engages in the development, manufacturing, logistics, and distribution of consumer and institutional products. This includes the Hoover® HOME LED lighting product line.

Capstone Companies develops, manufactures, and sells a wide spectrum of stylish, inventive, and user-friendly LED lighting products. These include bath vanity lights, multi-task lights, patented power failure light bulbs, portable accent lighting, and power failure multi-function handheld lights. Products also include power failure plug-in decorative lighting, multi-function nightlights, outdoor LED fixtures, under cabinet lighting, and wireless motion sensor lights. 

In the Power Failure category, Capstone developed and launched in 2008 its first power failure product - the 6 LED Eco-i-lite Multi-Function LED light. The Company’s new 3-in-1 Compact 6 LED Light provides power failure protection with the added value of a nightlight feature. A major selling point of Capstone’s Power Failure products is the ability for retailers to sell numerous power failure products to individual consumers over time.

Regarding Safety & Security solutions, Capstone has expanded its product portfolio addressing the need for improved safety and security product applications for consumers’ everyday lives.  Capstone’s first products, Battery Powered Wireless Motion Detector Lights are gaining momentum at retail.

Recently, Capstone Companies reported its financial results for Q1 2017. For Q1 its Revenue of $6.8 million exceeded guidance of $5.5 million. In addition, it more than tripled from $2.1 million in the prior-year period. Gross Profit more than doubled to $1.6 million over the year-ago period.

Capstone Companies’ Chief Executive Officer, Mr. Stewart Wallach, said, “The continued strong interest in our LED lighting products produced another record backlog level at the end of the first quarter. The order activity and backlog level drives our expectation that the second quarter of 2017 will exceed the same prior-year period and be the strongest second quarter in company’s history.”

Capstone Companies, Inc. (CAPC), closed Friday's trading session at $0.56999, down 0.54%, on 1,154 volume with 3 trades. The average volume for the last 60 days is 55,309 and the stock's 52-week low/high is $0.21/$0.95.


The QualityStocks
Company Corner


ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $0.89, even for the day, on 37,765 volume with 51 trades. The stock’s average daily volume over the past 60 days is 48,794 and its 52-week low/high is $0.12/$2.75.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW pursuing opportunities in the cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products. To view the full publication, visit: https://www.networknewswire.com/5-standout-legal-cannabis-companies-worthy-consideration/

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

NetworkNewsWire Announces Publication Discussing a Variety of Cannabis Investment Options

ChineseInvestors.com, Inc. to Attend the Southern California Investment Forum and FreedomFest 10th Anniversary

NetworkNewsWire Announces Publication that Highlights Several Public Companies, Including ChineseInvestors.com, Inc. (OTCQB: CIIX), Which Are Taking Advantage of the Mounting Acceptance of Digital Currency

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.60, up 5.26%, on 71,454 volume with 26 trades. The stock’s average daily volume over the past 60 days is 35,690 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Executing Aggressive Expansion Strategy with Introduction of Third Service Line

ORHub, Inc. Signs National Deployment Agreement to Roll-out Transformative Medical Software in Major U.S. Markets

Microsoft Publication Demonstrates Vital Capabilities of ORHub, Inc.'s Surgical Resource Management Solution

Lexaria Bioscience Corp. (LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.35, up 4.48%, on 72,704 volume with 45 trades. The stock’s average daily volume over the past 60 days is 84,870 and its 52-week low/high is $0.0913/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

National Research Council and Lexaria Bioscience Commence Laboratory Work

Lexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is “One to Watch”

Players Network, Inc. (PNTV)

The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.178, up 2.65%, on 1,664,191 volume with 272 trades. The stock’s average daily volume over the past 60 days is 4,263,923, and its 52-week low/high is $0.0023/$0.231.

Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.

Green Leaf Farms Holdings, LLC (Green Leaf)

Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.

Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.

They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.

Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.

Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.


WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.

Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.

WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.

By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.

Marijuana and Media Strategy

While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer

Players Network, Inc. Company Blog

Players Network, Inc. News:

Player's Network's Weed TV to Live Broadcast First Recreational Marijuana Transaction at Pisos Dispensary in Las Vegas

Player's Network, Inc. Appoints Geoffrey Lawrence, Nevada Assistant State Controller, as Chief Financial Officer, Chief Compliance Officer

Player's Network, Inc. CEO Featured on MoneyTV with Donald Baillargeon, 6/2

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.26, off by 4.06%, on 489,150 volume with 164 trades. The stock’s average daily volume over the past 60 days is 415,555, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

InMed Signs R&D Agreement with ATERA

InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Stock Beast
(TEAR) +89.77%


Wall Street Mover
(BONT) +17.66%


(PLUG) +15.09%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251